Opin vísindi

A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma

A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma


Titill: A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
Höfundur: Smith, Dirk
Helgason, Hannes
sulem, patrick   orcid.org/0000-0001-7123-6123
Björnsdóttir, Unnur Steina
Lim, Ai Ching
Sveinbjörnsson, Garðar
Hasegawa, Haruki
Brown, Michael
Ketchem, Randal R.
Gavala, Monica
... 30 fleiri höfundar Sýna alla höfunda
Útgáfa: 2017-03-08
Tungumál: Enska
Umfang: e1006659
Háskóli/Stofnun: Háskóli Íslands
University of Iceland
Svið: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Verkfræði- og náttúruvísindasvið (HÍ)
School of Engineering and Natural Sciences (UI)
Deild: Læknadeild (HÍ)
Faculty of Medicine (UI)
Birtist í: PLoS Genetics;13(3)
ISSN: 1553-7390
1553-7404 (eISSN)
DOI: 10.1371/journal.pgen.1006659
Efnisorð: Erfðafræði; Asma; Ofnæmi
URI: https://hdl.handle.net/20.500.11815/293

Skoða fulla færslu

Tilvitnun:

Smith D, Helgason H, Sulem P, Bjornsdottir US, Lim AC, Sveinbjornsson G, et al. (2017) A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet 13(3): e1006659. doi:10.1371/journal.pgen.1006659

Útdráttur:

IL-33 is a tissue-derived cytokine that induces and amplifies eosinophilic inflammation and has emerged as a promising new drug target for asthma and allergic disease. Common variants at IL33 and IL1RL1, encoding the IL-33 receptor ST2, associate with eosinophil counts and asthma. Through whole-genome sequencing and imputation into the Icelandic population, we found a rare variant in IL33 (NM_001199640:exon7:c.487-1G>C (rs146597587-C), allele frequency = 0.65%) that disrupts a canonical splice acceptor site before the last coding exon. It is also found at low frequency in European populations. rs146597587-C associates with lower eosinophil counts (β = -0.21 SD, P = 2.5×10–16, N = 103,104), and reduced risk of asthma in Europeans (OR = 0.47; 95%CI: 0.32, 0.70, P = 1.8×10–4, N cases = 6,465, N controls = 302,977). Heterozygotes have about 40% lower total IL33 mRNA expression than non-carriers and allele-specific analysis based on RNA sequencing and phased genotypes shows that only 20% of the total expression is from the mutated chromosome. In half of those transcripts the mutation causes retention of the last intron, predicted to result in a premature stop codon that leads to truncation of 66 amino acids. The truncated IL-33 has normal intracellular localization but neither binds IL-33R/ST2 nor activates ST2-expressing cells. Together these data demonstrate that rs146597587-C is a loss of function mutation and support the hypothesis that IL-33 haploinsufficiency protects against asthma.

Leyfi:

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:


Fletta

Um vefinn

Reikningurinn minn